392 results match your criteria: "and the Perelman School of Medicine[Affiliation]"
JACC Adv
January 2025
Division of Cardiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Background: Individuals have a higher risk of cardiovascular disease later in life if they give birth to a child with congenital heart disease (CHD). The mechanism of this association has not been well documented.
Objectives: The authors aimed to describe the prevalence of cardiovascular disease and risk factors in women and birthing individuals 18 to 23 years after delivery of a child with CHD compared to normative data.
J Clin Oncol
December 2024
Ti-Cheng Chang, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN; Wenan Chen, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, Division of Computational Biology, Mayo Clinic, Rochester, MN; Chunxu Qu, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Zhongshan Cheng, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN; Abdelrahman Elsayed, PhD and Stanley B. Pounds, PhD, Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; Mary Shago, PhD, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Karen R. Rabin, MD, PhD, Department of Pediatrics, Baylor College of Medicine, Houston, TX; Elizabeth A. Raetz, MD, Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY; Meenakshi Devidas, PhD, Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN; Cheng Cheng, PhD, Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; Anne Angiolillo, MD, Children's National Medical Center, Washington, DC; Pradyuamma Baviskar, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Michael Borowitz, MD, Department of Pathology, Johns Hopkins University, Baltimore, MD; Michael J. Burke, MD, Division of Pediatric Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI; Andrew Carroll, PhD, Department of Genetics, University of Alabama at Birmingham, Birmingham, AL; William L. Carroll, MD, Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY; I-Ming Chen, DVM and Richard Harvey, PhD, Department of Pathology, University of New Mexico, Albuquerque, NM; Nyla Heerema, PhD, The Ohio State University, Columbus, OH; Ilaria Iacobucci, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Jeremy R. Wang, PhD, Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Sima Jeha, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; Eric Larsen, MD, Department of Pediatrics, Maine Children's Cancer Program, Scarborough, ME; Leonard Mattano, MD, HARP Pharma Consulting, Mystic, CT; Kelly Maloney, MD, Department of Pediatrics and Children's Hospital Colorado, University of Colorado, Aurora, CO; Ching-Hon Pui, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; Nilsa C. Ramirez, MD, Institute for Genomic Medicine and Biopathology Center, Nationwide Children's Hospital, Departments of Pathology and Pediatrics, Ohio State University, Columbus, OH; Wanda Salzer, MD, Uniformed Services University, School of Medicine, Bethesda, MD; Cheryl Willman, MD, Department of Laboratory Medicine and Pathology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN; Naomi Winick, MD, Department of Pediatric Hematology Oncology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Brent Wood, MD, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA; Stephen P. Hunger, MD, Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Gang Wu, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Charles G. Mullighan, MBBS, MD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; and Mignon L. Loh, MD, Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.
Cells
December 2024
Institute for Biomedical Technologies, National Research Council, 56124 Pisa, Italy.
Cornelia de Lange syndrome (CdLS) is a rare, dominantly inherited multisystem developmental disorder. Pathogenic variants in genes encoding the structural subunits and regulatory proteins of the cohesin complex (, , , , and ) are the primary contributors to the pathogenesis of CdLS. Pathogenic variations in these genes disrupt normal cohesin function, leading to the syndrome's diverse and complex clinical presentation.
View Article and Find Full Text PDFN Engl J Med
December 2024
From the Division of Haematology-Oncology (S.G., S.A., S.Z.), the Faculty of Medicine (S.G., S.A.), and the Department of Laboratory Medicine and Pathobiology, University of Toronto (M.S.), Toronto, and British Columbia Children's Hospital, University of British Columbia, Vancouver (A.M.L.) - all in Canada; Seattle Children's Hospital (R.E.R., T.H.-W., M.L.L.), the Ben Towne Center for Childhood Cancer and Blood Disorders Research and the Department of Pediatrics, Fred Hutchinson Cancer Center, University of Washington (R.E.R., M.L.L.), and Adaptive Biotechnologies (I.K.) - all in Seattle; the Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville (J.A.K., C.W., S.C.); the Division of Pediatric Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston (K.R.R.), Children's Blood and Cancer Center and Dell Children's Medical Center of Central Texas, Austin (H.R.K.), and the Department of Pediatrics, Division of Pediatric Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas (N.W.) - all in Texas; Servier Pharmaceuticals, Boston (A.L.A.); the Department of Genetics, University of Alabama at Birmingham, Birmingham (A.J.C.); Children's Hospital Colorado and the University of Colorado School of Medicine, Aurora (L.G., M.M.O.); the Division of Pediatric Hematology-Oncology, University of Utah, Primary Children's Hospital, Salt Lake City (J.L.M.); the Children's Oncology Group, Monrovia (O.M.), the Department of Pediatric Hematology-Oncology, MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach (M.O.), the Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles (B.L.W.), and Amgen, Thousand Oaks (F.Z.) - all in California; the Department of Pediatrics, Emory University School of Medicine, Atlanta (T.P.M.); the Steve and Cindy Rasmussen Institute for Genomic Medicine and the Biopathology Center, Nationwide Children's Hospital (S.C.R.) and the Biopathology Center and Children's Oncology Group Biospecimen Bank, Nationwide Children's Hospital (Y.M., E.W.) - both in Columbus, OH; Amgen Research, Munich, Germany (G.Z.); the Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN (M.D.); the Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania - both in Philadelphia (S.P.H., D.T.T.); and the Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York (E.A.R.).
Background: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.
View Article and Find Full Text PDFAntimicrob Agents Chemother
December 2024
Children's Hospital of Orange County, Orange, and University of California, Irvine, California, USA.
Pharmacol Ther
December 2024
RTI International, Research Triangle Park, NC, United States of America.
Programs for preclinical testing of targeted cancer agents in murine models of childhood cancers have been supported by the National Cancer Institute (NCI) since 2004. These programs were established to work collaboratively with industry partners to address the paucity of targeted agents for pediatric cancers compared with the large number of agents developed and approved for malignancies primarily affecting adults. The distinctive biology of pediatric cancers and the relatively small numbers of pediatric cancer patients are major challenges for pediatric oncology drug development.
View Article and Find Full Text PDFPediatr Res
October 2024
Department of Pediatrics, UChicago Medicine at the University of Chicago, Chicago, US.
The pediatric subspecialty workforce is challenged by shortages and geographic maldistribution of subspecialists. We invited leaders in pediatrics to discuss how the field's vitality and survival can be secured. These leaders presented their own opinions and not the opinion of the society or organization that they are presenting.
View Article and Find Full Text PDFMed Teach
October 2024
Perelman School of Medicine, University of Pennsylvania in Philadelphia, PA, USA.
Circulation
October 2024
Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy (N.M., C.F., I.O.).
Curr Opin Endocr Metab Res
September 2024
Hospital of the University of Pennsylvania, Department of Medical Genetics, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors which secrete catecholamines, causing cardiovascular compromise. While isolated tumors and locoregional disease can be treated surgically, treatment options for metastatic disease are limited, and no targeted therapies exist. Approximately 25% of PPGL are causatively associated with germline pathogenic variants, which are known risk factors for multifocal and metastatic PPGL.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
September 2024
The Children's Hospital of Philadelphia and The Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Objective: We linked pharmacy dispensing data to clinical data in the electronic health record (EHR) to (1) identify characteristics associated with adherence to methotrexate (MTX) and (2) determine the association between adherence and disease activity in patients with juvenile idiopathic arthritis (JIA).
Methods: We conducted a single-center retrospective cohort study of incident MTX recipients with JIA treated between January 2016 and September 2023 for ≥12 months. Using pharmacy dispensing data, complemented by EHR data, we estimated adherence using medication possession ratios (MPRs) over the first 365 days of treatment.
J Clin Endocrinol Metab
September 2024
Department of Pediatrics, Golisano Children's Hospital, The University of Rochester School of Medicine and Dentistry.
Context: The adverse skeletal effects of type 1 diabetes (T1D) include deficient bone accrual and lifelong increased fracture risk. The contributors to impaired bone accrual in people with T1D are incompletely understood.
Objective: To determine if urinary calcium excretion is associated with impaired bone accrual in youth with T1D and to characterize the contribution of glycemic control and markers of bone mineral metabolism to urinary calcium excretion.
J Clin Oncol
October 2024
Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.
Radiother Oncol
September 2024
Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Prognosis for patients with high-risk neuroblastoma (HR-NBL) is guarded despite aggressive therapy, and few studies have characterized outcomes after radiotherapy in relation to radiation treatment fields.
Methods: Multi-institutional retrospective cohort of 293 patients with HR-NBL who received autologous stem cell transplant (ASCT) and EBRT between 1997-2021. LRR was defined as recurrence at the primary site or within one nodal echelon beyond disease present at diagnosis.
JAMA Netw Open
May 2024
Department of Biostatistics, Epidemiology, and Informatics, the Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Importance: Neurodevelopmental outcomes for children with congenital heart defects (CHD) have improved minimally over the past 20 years.
Objectives: To assess the feasibility and tolerability of maternal progesterone therapy as well as the magnitude of the effect on neurodevelopment for fetuses with CHD.
Design, Setting, And Participants: This double-blinded individually randomized parallel-group clinical trial of vaginal natural progesterone therapy vs placebo in participants carrying fetuses with CHD was conducted between July 2014 and November 2021 at a quaternary care children's hospital.
Ann Thorac Surg
May 2024
Section of Pediatric Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri.
The Society of Thoracic Surgeons (STS) Congenital Heart Surgery Database (CHSD) continues to be the most comprehensive database of congenital and pediatric cardiothoracic surgical procedures in the world and contains information on 664,210 operations as of June 30, 2023. The 35th harvest of the STS CHSD data was undertaken in Spring 2023, spanning the 4-year period January 1, 2019, through December 31, 2022, and included 144,919 operations performed at 114 participating sites in North America. The harvest analysis was successfully executed by the STS Research and Analytic Center.
View Article and Find Full Text PDFLeukemia
April 2024
Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, FL, USA.
Pediatr Blood Cancer
April 2024
Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Background: The primary objective was to measure the proportion of episodes where care delivery was inconsistent with selected recommendations of a clinical practice guideline (CPG) on fever and neutropenia (FN) management. The influence of site size on CPG-inconsistent care delivery, and association between patient outcomes and CPG-inconsistent care were described.
Methods: This retrospective, multicenter study included patients less than 21 years old with cancer who were at high risk of poor FN outcomes and were previously enrolled to a Children's Oncology Group (COG) study at participating National Cancer Institute Community Oncology Research Program (NCORP) institutions from January 2014 through December 2015.
Pediatr Pulmonol
April 2024
Department of Pediatrics, The Children's Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cancer Discov
January 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
In the first prospective study evaluating circulating tumor DNA (ctDNA) for early cancer detection, Wong, Luo, and colleauges demonstrate the feasibility of liquid biopsy as an augmentation to current surveillance protocols for patients with Li-Fraumeni syndrome, an inherited cancer predisposition associated with high cancer risk in both pediatric and adult populations. Though additional clinical validation in larger cohorts is needed, this research highlights that a multimodal approach is likely necessary to improve the sensitivity of liquid biopsy assays for early cancer detection. See related article by Wong, Lou et al.
View Article and Find Full Text PDFCardiol Young
May 2024
Division of Cardiothoracic Surgery, Department of Surgery, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: Cholestasis characterised by conjugated hyperbilirubinemia is a marker of hepatobiliary dysfunction following neonatal cardiac surgery. We aimed to characterise the incidence of conjugated hyperbilirubinemia following neonatal heart surgery and examine the effect of conjugated hyperbilirubinemia on post-operative morbidity and mortality.
Methods: This was a retrospective study of all neonates who underwent surgery for congenital heart disease (CHD) at our institution between 1/1/2010 and 12/31/2020.
JAMIA Open
December 2023
Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, United States.
Objectives: Pediatric emergence delirium is an undesirable outcome that is understudied. Development of a predictive model is an initial step toward reducing its occurrence. This study aimed to apply machine learning (ML) methods to a large clinical dataset to develop a predictive model for pediatric emergence delirium.
View Article and Find Full Text PDFAm J Med Genet A
April 2024
Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, California, USA.
Patent ductus arteriosus (PDA) and coarctation of the aorta (CoA) are relatively common congenital heart defects. Pathogenic variants in PRDM6, which encodes a smooth-muscle-cell-specific transcription factor, have now been etiologically associated with non-syndromic PDA. We present three patients with PDA and CoA found to harbor PRDM6 variants, including a novel, likely-pathogenic variant.
View Article and Find Full Text PDFKidney Int
March 2024
Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA. Electronic address:
Creatinine and cystatin-C are recommended for estimating glomerular filtration rate (eGFR) but accuracy is suboptimal. Here, using untargeted metabolomics data, we sought to identify candidate filtration markers for a new targeted assay using a novel approach based on their maximal joint association with measured GFR (mGFR) and with flexibility to consider their biological properties. We analyzed metabolites measured in seven diverse studies encompasing 2,851 participants on the Metabolon H4 platform that had Pearson correlations with log mGFR and used a stepwise approach to develop models to < -0.
View Article and Find Full Text PDFCommun Med (Lond)
September 2023
Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.